Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01930786 · ClinicalTrials.gov registry record
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 744
- Enrollment target
NCT01930786 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 744 participants.
The verdict
NCT01930786 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 744 participants
- Enrollment target
Study Summary
This is a registry study in adults with spasticity to determine onabotulinumtoxinA use in clinical practice. Treatment will be administered in accordance with physician standard practice. All treatment decisions lie with the physician.
Interventions
- DRUG onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2013-10-16 |
| Est. Completion | 2017-10-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01930786
The ClinicalTrials.gov registry entry for NCT01930786 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 744 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which onabotulinumtoxinA is the first listed.
NCT01930786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01930786 about?
NCT01930786 is a clinical study titled "An Adult Spasticity Registry of OnabotulinumtoxinA Treatment". This is a registry study in adults with spasticity to determine onabotulinumtoxinA use in clinical practice. Treatment will be administered in accordance with physician standard practice. All treatment decisions lie with the physician.
What is the current status of trial NCT01930786?
This trial is currently completed. The enrollment target is 744 participants. The study started on 2013-10-16. Estimated completion is 2017-10-09.
What interventions are being tested in trial NCT01930786?
The interventions under investigation include: onabotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT01930786?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.